

DCAT
TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*



1. [Bayer Ups Offer to Acquire Monsanto to Approximately \\$65 Billion](#)

Making its first large-scale acquisition since becoming a pure-play life sciences company, Bayer has raised its all-cash offer to acquire, Monsanto, an agricultural chemical and seed company, from \$122 to \$125 per share or from approximately \$62 billion to \$65 billion. Crop science is one piece of a three-pronged strategic focus in life sciences for Bayer, which also includes pharmaceuticals and consumer healthcare. [Read More](#)

2. [Sagent, Nichi-Iko Agree to Merge in \\$736 Million Deal](#)

In a generics deal, Nichi-Iko Pharmaceutical Co., Ltd., a Japan-headquartered generic drug company, and Sagent Pharmaceuticals have entered into a definitive merger agreement under which Nichi-Iko will acquire Sagent via an all-cash tender offer followed by a second-step merger for a total consideration of approximately \$736 million. [Read More](#)

3. [Pfizer, NovaMedica Partner for Manufacturing Plant and Products in Russia](#)

Pfizer and NovaMedica, a Russian pharmaceutical company, have formed a long-term strategic partnership to locally manufacture in Russia and bring to the Russian market a number of medicines. Pfizer plans to invest in NovaMedica's construction of a new manufacturing plant in the Kaluga region in Russia and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner. [Read More](#)

4. [Amgen, Daiichi Sankyo Form Biosimilars Pact; Amgen Advances Humira Biosimilar](#)

Amgen and Daiichi Sankyo have formed an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab. Amgen also will meet with the FDA to discuss its application for a biosimilar of Humira (adalimumab). [Read More](#)

5. [FDA Advisory Committee Recommends Sandoz's Biosimilar of Enbrel](#)

A FDA advisory committee has recommended approval of Sandoz's proposed biosimilar for etanercept, which is the active ingredient in the innovator biologic, Enbrel. The committee voted in support for all five indications of the reference product, including rheumatoid arthritis, plaque psoriasis, psoriatic psoriasis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis. [Read More](#)

6. [Cipla To Invest \\$91 Million For New Biotech Manufacturing Facility](#)

Cipla plans to expand its biosimilars manufacturing capacity with a \$91 million investment in a new biotech manufacturing facility in South Africa. Construction is expected to begin in early 2017 with the

facility scheduled to come on line in the third quarter of 2018. [Read More](#)

7. AMRI Completes Acquisition of Euticals

AMRI has completed its EUR 315 million (\$349 million) acquisition of Prime European Therapeutics S.p.A., also known as Euticals, a privately held company headquartered in Lodi, Italy, specializing in custom synthesis and the manufacture of active pharmaceutical ingredients. [Read More](#)

8. Vetter Plans \$320 Million Investment for US Commercial Manufacturing Facility

Vetter plans to invest approximately \$320 million for construction and improvements for a site for commercial manufacturing in Des Plaines, Illinois over more than 10 years. The 18-acre site would include 1,138,237 square feet of facility space, and if approved, would be the company's second US manufacturing site. Vetter now has a small-scale manufacturing facility in the US. [Read More](#)

9. Cambrex Completes \$50 Million API Manufacturing and Storage Expansion

Cambrex has completed and validated a \$50-million production and warehousing expansion for active pharmaceutical ingredients at its cGMP site in Charles City, Iowa. Cambrex's Charles City, Iowa facility sits on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. [Read More](#)

10. GE Healthcare Acquires Swiss Biotech Tool Firm

GE Healthcare is further investing in cell therapy with the acquisition of the Swiss firm, Biosafe, a designer and manufacturer of automated cell-processing systems. This acquisition follows earlier investments the company has made for cell therapy and regenerative medicine capabilities and technology. [Read More](#)

*****Upcoming DCAT Event*****

DCAT Announces Its Newest Member Networking Event

Enjoy all that Barcelona has to offer while making valuable industry connections at **DCAT After the Show**, DCAT's newest member networking event held immediately following CPhI Worldwide in Barcelona on Wednesday, October 5, from 6:00 PM to 8:30 PM. Located at the beautiful Casa Llotja de Mar, this venue is just steps away from the Gothic Quarter and Port of Barcelona, offering member company representatives the perfect opportunity to engage with colleagues they may have missed at the show before attending their customer events.

Registration for this event will open July 20, 2016. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org